
Opinion|Videos|March 6, 2025
New Intravesical Delivery Systems and TAR-200 in NMIBC
Experts review different treatment delivery options available for the management of non–muscle-invasive bladder cancer (NMIBC), discuss the exciting developments in NMIBC with several delivery systems and agents under investigation, and provide information about TAR-200, a targeted release system utilizing continuous intravesical release of gemcitabine, including how TAR-200 is installed within the bladder.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please review different treatment delivery options available for management of NMIBC.
- It is an exciting time for NMIBC, as several delivery systems and agents are currently under investigation for treatment of NMIBC.
- To start with, please share information about TAR-200, a targeted release system that utilizes continuous intravesical release of gemcitabine.
- Describe how TAR-200 is installed within the bladder.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












